BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pouillon L, Baumann C, Rousseau H, Choukour M, Andrianjafy C, Danese S, Peyrin-biroulet L. Treatment Persistence of Infliximab Versus Adalimumab in Ulcerative Colitis: A 16-Year Single-Center Experience. Inflammatory Bowel Diseases 2019;25:945-54. [DOI: 10.1093/ibd/izy322] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Gao W, Wang C, Yu L, Sheng T, Wu Z, Wang X, Zhang D, Lin Y, Gong Y. Chlorogenic Acid Attenuates Dextran Sodium Sulfate-Induced Ulcerative Colitis in Mice through MAPK/ERK/JNK Pathway. Biomed Res Int 2019;2019:6769789. [PMID: 31139644 DOI: 10.1155/2019/6769789] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
2 Kobayashi T, Udagawa E, Uda A, Hibi T, Hisamatsu T. Impact of immunomodulator use on treatment persistence in patients with ulcerative colitis: A claims database analysis. J Gastroenterol Hepatol 2020;35:225-32. [PMID: 31397010 DOI: 10.1111/jgh.14825] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
3 Blesl A, Binder L, Högenauer C, Wenzl H, Borenich A, Pregartner G, Berghold A, Mestel S, Kump P, Baumann-Durchschein F, Petritsch W. Limited long-term treatment persistence of first anti-TNF therapy in 538 patients with inflammatory bowel diseases: a 20-year real-world study. Aliment Pharmacol Ther 2021;54:667-77. [PMID: 34151449 DOI: 10.1111/apt.16478] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
4 Lee YI, Park Y, Park SJ, Kim TI, Kim WH, Cheon JH. Comparison of Long-Term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naïve Patients with Ulcerative Colitis. Gut Liver 2021;15:232-42. [PMID: 32616683 DOI: 10.5009/gnl19433] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Kim ES. Infliximab versus Adalimumab, Which One Is Better for Ulcerative Colitis? Gut Liver 2021;15:149-50. [PMID: 33716221 DOI: 10.5009/gnl210098] [Reference Citation Analysis]
6 Bargo D, Tritton T, Cappelleri JC, DiBonaventura M, Smith TW, Tsuchiya T, Gardiner S, Modesto I, Holbrook T, Bluff D, Kobayashi T. Living with Ulcerative Colitis in Japan: Biologic Persistence and Health-Care Resource Use. Inflamm Intest Dis 2021;6:186-98. [PMID: 35083284 DOI: 10.1159/000519123] [Reference Citation Analysis]
7 Papamichael K, Lin S, Moore M, Papaioannou G, Sattler L, Cheifetz AS. Infliximab in inflammatory bowel disease. Ther Adv Chronic Dis 2019;10:2040622319838443. [PMID: 30937157 DOI: 10.1177/2040622319838443] [Cited by in Crossref: 33] [Cited by in F6Publishing: 19] [Article Influence: 11.0] [Reference Citation Analysis]
8 Fumery M, Filippi J, Abitbol V, Biron A, Laharie D, Serrero M, Altwegg R, Bouhnik Y, Peyrin-Biroulet L, Gilletta C, Roblin X, Pineton de Chambrun G, Vuitton L, Bourrier A, Nancey S, Gornet JM, Nahon S, Bouguen G, Viennot S, Nachury M, Amiot A. Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study. Aliment Pharmacol Ther 2021. [PMID: 34296456 DOI: 10.1111/apt.16544] [Reference Citation Analysis]
9 Gil-candel M, Gascón-cánovas JJ, Urbieta-sanz E, Rentero-redondo L, Onteniente-candela M, Iniesta-navalón C. Comparison of drug survival between infliximab and adalimumab in inflammatory bowel disease. Int J Clin Pharm 2020;42:500-7. [DOI: 10.1007/s11096-020-00978-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
10 Bastida G, Marín-Jiménez I, Forés A, García-Planella E, Argüelles-Arias F, Tagarro I, Fernandez-Nistal A, Montoto C, Aparicio J, Aguas M, Santos-Fernández J, Boscá-Watts MM, Ferreiro-Iglesias R, Merino O, Aldeguer X, Cortés X, Sicilia B, Mesonero F, Barreiro-de Acosta M. Treatment patterns and intensification within 5 year of follow-up of the first-line anti-TNFα used for the treatment of IBD: Results from the VERNE study. Dig Liver Dis 2021:S1590-8658(21)00319-4. [PMID: 34244110 DOI: 10.1016/j.dld.2021.06.005] [Reference Citation Analysis]
11 Macaluso FS, Maida M, Grova M, Crispino F, Teresi G, Orlando A, Orlando A. Head-to-head comparison of biological drugs for inflammatory bowel disease: from randomized controlled trials to real-world experience. Therap Adv Gastroenterol 2021;14:17562848211010668. [PMID: 33995582 DOI: 10.1177/17562848211010668] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Srinivasan A, van Langenberg DR. Editorial: does anti-TNF "treatment persistence" always equate to "effective treatment"? Only objective disease assessments can answer the question. Aliment Pharmacol Ther 2021;54:718-9. [PMID: 34379842 DOI: 10.1111/apt.16506] [Reference Citation Analysis]
13 Visuri I, Eriksson C, Olén O, Cao Y, Mårdberg E, Grip O, Gustavsson A, Hjortswang H, Karling P, Montgomery S, Myrelid P, Ludvigsson JF, Halfvarson J; SWIBREG study group. Predictors of drug survival: A cohort study comparing anti-tumour necrosis factor agents using the Swedish inflammatory bowel disease quality register. Aliment Pharmacol Ther 2021;54:931-43. [PMID: 34286871 DOI: 10.1111/apt.16525] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]